Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553349 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| SCHEMBL1554113 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL1770829 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL6559174 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL1770831 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL5453930 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL2474313 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL6559893 | 0.97 | ROCK2 (0.97) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL6559887 | 0.97 | ROCK2 (0.97) | ROCK2ROCK1KDM4EL3MBTL1KMT2A | |
| SCHEMBL5463779 | 0.88 | ROCK2 (0.78) | ROCK2ROCK1KDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| CN-119432708-A | In vitro induction method of gastric organoids and application thereof | 广州国家实验室 | 2025-02-14 | — | — | CN | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4005574-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | UNIV SANTIAGO COMPOSTELA (ES) | 2024-07-03 | — | — | EP | claimed |
| US-20230172944-A1 | ROCK INHIBITORS FOR USE IN TREATING OR PREVENTING PULMONARY EDEMA | ATRIVA THERAPEUTICS GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4138846-A1 | ROCK INHIBITORS FOR USE IN TREATING OR PREVENTING PULMONARY EDEMA | Atriva Therapeutics GmbH (DE) | 2023-03-01 | — | — | EP | claimed |
| CN-115666580-A | ROCK inhibitors for treating or preventing pulmonary edema | 归属疗法有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-114401725-A | Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of levodopa-induced dyskinesia | 圣地亚哥德·冈波忒拉大学 | 2022-04-26 | — | — | CN | claimed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| US-20030165576-A1 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-04 | — | — | US | claimed |
| US-20030125351-A1 | Agent for prophylaxis and treatment of glaucoma | AZUMA MITSUYOSHI (JP) | 2003-07-03 | — | — | US | claimed |
| US-20030096843-A1 | Preventives/remedies for kidney diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-22 | — | — | US | claimed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | claimed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | claimed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | claimed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | claimed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096843-A1 | Preventives/remedies for kidney diseases | RHOA, ROCK1, MMP1 | ROCK2 6/4885ROCK1 2/4885KDM4E 1848/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | ROCK2 90/4885ROCK1 186/4885KDM4E 961/4885 |
| US-20030125351-A1 | Agent for prophylaxis and treatment of glaucoma | ROCK1, PDE3A, RHOA | ROCK2 10/4885ROCK1 1/4885KDM4E 4153/4885 |
| US-20030165576-A1 | Antitumor effect potentiators | RHOT2, ROCK2, CIT | ROCK2 2/4885ROCK1 5/4885KDM4E 1158/4885 |
| US-20230172944-A1 | ROCK INHIBITORS FOR USE IN TREATING OR PREVENTING PULMONARY EDEMA | ROCK1, ROCK2, NHERF1 | ROCK2 2/4885ROCK1 1/4885KDM4E 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.